Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT00390221 · COMPLETED

Trial details

NCT number: NCT00390221
Sponsor: Biogen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsing-Remitting Multiple Sclerosis

Start date: 2008-02-01
Primary completion: 2011-05-01
Enrollment: 621

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.